Search

Background: Total ankle replacement is an established treatment for end-stage arthritis. However, there is little data examining outcomes in sequential bilateral replacements. This study aimed to compare outcomes between first and second ankles in sequential replacement., Methods: Patients were retrospectively contacted to complete a follow-up questionnaire including the Manchester-Oxford Foot Questionnaire (MOXFQ), EQ-5D-3 L, and a question assessing satisfaction. Electronic records identified demographics, procedural details, and complications., Results: Twenty patients underwent sequential bilateral ankle replacement over the study period. At a mean follow-up of four years, 18 patients completed the follow-up questionnaire. There was no statistically significant difference between first and second ankles in terms of MOXFQ score, EQ-5D-3 L or satisfaction. Eleven complications were noted., Conclusions: We report excellent outcomes after sequential bilateral ankle replacement with no difference in outcomes between first and second ankles. These results can be used to counsel patients in the future and manage expectations., Level of Evidence: IV., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hisham Shalaby reports a relationship with Stryker that includes: consulting or advisory. John C McKinley reports a relationship with Stryker that includes: travel reimbursement. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 European Foot and Ankle Society. Published by Elsevier Ltd. All rights reserved.)

The fixed-bearing Infinity implant (Wright Medical Group) for total ankle arthroplasty (TAA) was introduced to the U.K. market in 2014 and has rapidly become the most commonly used TAA implant. This is a follow-up report of a multicenter, non-designer, prospective observational study of 503 Infinity fixed-bearing TAA implants. The average follow-up of patients in the current report was 44.9 months (range, 28.3 to 63.9 months). The primary aim was to assess survivorship, complications, and reoperations. Secondary aims were to assess radiographic outcomes and patient-reported outcome measures (PROMs) and the influence of patient factors at 2 years. Four hundred and sixty-nine implants were evaluated at 2-year follow-up. Fifteen patients died, 8 withdrew, and 3 were lost to follow-up. The 2-year survivorship was 98.8%, and the non-revision reoperation rate was 2.8%. There was a significant improvement across all functional outcome scores from baseline to 2 years. The early experience and small rate of adverse events reported in this study continue to support the use of the Infinity TAA implant for the treatment of end-stage ankle arthritis. Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence. [ABSTRACT FROM AUTHOR]